What biomarker tests are recommended for Non-Small Cell Lung Cancer

Biomarker Testing for Non-Small Cell Lung Cancer

Biomarker testing is a crucial part of your NSCLC care because it identifies specific characteristics of your cancer that determine which treatments will work best for you. Think of biomarkers as biological "fingerprints" that help your doctors personalize your treatment plan.

Why Biomarker Testing Matters

According to the NCCN Guidelines for Non-Small Cell Lung Cancer, biomarker tests look for biological clues that differ between people. A treatment that helps one person might not help another—biomarker testing ensures you get the most effective option for YOUR specific cancer.

Recommended Biomarker Tests

Driver Mutations (Genetic Changes That Fuel Cancer Growth)

The NCCN Guidelines recommend testing for these driver mutations in nonsquamous NSCLC (adenocarcinoma, large cell carcinoma):

• EGFR mutations – Found in about 1 in 3 people with metastatic adenocarcinoma; these mutations make cancer cells grow faster
• ALK rearrangements – A genetic fusion that creates an abnormal protein driving cancer growth
• ROS1 rearrangements – Similar to ALK, this fusion protein fuels cancer cells
• BRAF V600E mutations – A specific genetic change that can be targeted with specific drugs
• KRAS G12C mutations – A common mutation (prognostic marker) that indicates how the cancer may behave
• MET exon 14 skipping mutations – A genetic alteration affecting a growth-promoting protein
• NTRK gene fusions – Rare but important genetic changes
• RET rearrangements – Another fusion protein that can be targeted
• ERBB2 (HER2) mutations – Similar to breast cancer HER2 testing

For squamous cell lung cancer, driver mutations are much less common, but testing may still be considered on a case-by-case basis.

PD-L1 Expression (Immune Checkpoint Protein)

All lung cancers should be tested for PD-L1, according to NCCN Guidelines. Here's why this matters:

PD-L1 is a protein on cancer cell surfaces that acts like a "shield"—it stops your immune system's T cells from attacking the cancer. Testing PD-L1 levels helps determine if immunotherapy (drugs that boost your immune system) will be effective for you.

Testing Methods

According to the NCCN Guidelines, biomarker testing can be done through:

• Tissue samples from biopsy or surgery (preferred method)
• Blood samples (plasma circulating tumor DNA or "liquid biopsy") – useful if tissue is limited or if you're not medically fit for invasive sampling
• Broad molecular profiling – testing multiple biomarkers simultaneously using Next-Generation Sequencing (NGS), which can detect many mutations at once

Important Considerations

Timing: Molecular testing can take up to 3 weeks for results, so plan accordingly.

If tissue is limited: If there isn't enough tissue from your biopsy, your doctor may:

• Schedule a second biopsy
• Use a blood sample for testing
• Use plasma circulating tumor DNA testing

Multiple mutations are rare: It's very uncommon for one cancer to have more than one driver mutation, so finding one typically means you won't need extensive additional testing.

Questions to Ask Your Healthcare Team

1. Which biomarkers has my cancer been tested for?
2. Do I have any driver mutations, and what treatment options does that open up?
3. What is my PD-L1 level, and what does that mean for immunotherapy?
4. If my initial tests were limited, should we do broader molecular profiling?
5. How long will the biomarker results take, and when will we discuss treatment options?

Key Takeaway

According to NCCN Guidelines, broad molecular profiling of all actionable biomarkers is strongly recommended because it helps many people get the best treatment for their specific cancer. Your oncologist will use these results to determine whether you're eligible for targeted therapies (drugs designed for specific mutations) or immunotherapies (drugs that boost your immune system).

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.